Silence Therapeutics plc, (Nasdaq: SLN), (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced...
Silence Therapeutics plc (“Silence” or the “Company”) , a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has...
Silence Therapeutics plc (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has...
Trial met its primary endpoint, with a significantly higher proportion of clinical responders on divesiran (88%) compared to placebo (19%); placebo-adjusted response rate = 69% ...
Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter...
Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results...
Barchart Research What to Expect from SLN Earnings SLN Generated August 5, 2026 Current Price $11.24 EPS Estimate $$-0.32 Consensus Rating Moderate Buy Average Move 5.76% Silence Therapeutics reports tomorrow...
New analyses from the Phase 1 SANRECO study demonstrate potential improvements in PV symptoms and quality-of-life Follow-up data show substantial reductions in phlebotomy...
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led...
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence...